RPRX Stock: Price, Earnings History and SEC Filings
Royalty Pharma plc (RPRX) last traded at $67.18, up 1.90% on the latest session and up 15.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.32 against an analyst estimate of $1.27, a beat of 3.9%.
$67.18 +1.90%
1 month+15.11%
52-week high$67.71
52-week low$36.03
Volume4.66M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RPRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $1.32 | $1.27 | +3.94% |
| Mar 2026 | May 6, 2026 | $1.30 | $1.22 | +6.56% |
| Dec 2025 | Feb 11, 2026 | $1.46 | $1.33 | +9.77% |
| Sep 2025 | Nov 5, 2025 | $1.17 | $1.11 | +5.41% |
RPRX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for RPRX
SEC filing data is not available right now. You can search for RPRX on SEC EDGAR.
RPRX news
- Zenas BioPharma Eyes Key Lupus and IL-17 Data as Obexelimab FDA Decision NearsOct 30, 2026 · marketbeat.com
- Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key MetricsOct 30, 2026 · finance.yahoo.com
- Should You Buy Royalty Pharma Stock Before Nov. 4?Oct 29, 2026 · fool.com
- Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOct 29, 2026 · finance.yahoo.com
- Royalty Pharma plc - Class AOct 28, 2026 · 247wallst.com
- Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOct 28, 2026 · finance.yahoo.com
- Funds Load Up On Marriott, Estee Lauder As Big Tech Earnings LoomOct 28, 2026 · finance.yahoo.com
- Analysts Estimate Alps Alpine Co Ltd. - Unsponsored ADR (APELY) to Report a Decline in Earnings: What to Look Out forOct 28, 2026 · msn.com
About Royalty Pharma plc
Royalty Pharma plc (RPRX) is a US-listed public company on Nasdaq.